Cargando…

Ribosome display for the rapid generation of high-affinity Zika-neutralizing single-chain antibodies

BACKGROUND: Zika virus (ZIKV) is an emerging pathogen with no approved therapeutics and only limited diagnostics available. To address this gap, six mouse single-chain antibodies (scFvs) to ZIKV envelope (E) protein were isolated rapidly and efficiently from a ribosome-displayed antibody library con...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunamneni, Adinarayana, Ye, Chunyan, Bradfute, Steven B., Durvasula, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6239285/
https://www.ncbi.nlm.nih.gov/pubmed/30444865
http://dx.doi.org/10.1371/journal.pone.0205743
_version_ 1783371530570301440
author Kunamneni, Adinarayana
Ye, Chunyan
Bradfute, Steven B.
Durvasula, Ravi
author_facet Kunamneni, Adinarayana
Ye, Chunyan
Bradfute, Steven B.
Durvasula, Ravi
author_sort Kunamneni, Adinarayana
collection PubMed
description BACKGROUND: Zika virus (ZIKV) is an emerging pathogen with no approved therapeutics and only limited diagnostics available. To address this gap, six mouse single-chain antibodies (scFvs) to ZIKV envelope (E) protein were isolated rapidly and efficiently from a ribosome-displayed antibody library constructed from the spleens of five immunized mice. METHODOLOGY/RESULTS: In this report, we have generated a panel of mouse scFvs to ZIKV E protein using ribosome display. The six scFvs demonstrated no cross-reactivity with DENV2 NGC envelope protein, suggesting specificity for ZIKV E protein. These scFvs showed differences in their affinity: two (scFv45-3, scFv63-1) of them were dominant after four rounds of panning, and showed higher affinity (an apparent Kd values from 19 to 27 nM) than the other four (scFv5-1, scFv7-2, scFv38-1, and scFv51-2). All six scFvs showed ZIKV-neutralizing activity in the plaque reduction neutralization test (PRNT) assay and their neutralizing activity was positively correlated with their affinities. CONCLUSIONS/SIGNIFICANCE: The scFvs (45–3 and 63–1) with highest affinity may have dual utility as diagnostics capable of recognizing ZIKV E subtypes and may be further developed to treat ZIKV infection. Our approach has the added advantage of generating Fc receptor-deficient antibodies, minimizing concern of antibody-dependent enhancement (ADE) of infection.
format Online
Article
Text
id pubmed-6239285
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-62392852018-12-01 Ribosome display for the rapid generation of high-affinity Zika-neutralizing single-chain antibodies Kunamneni, Adinarayana Ye, Chunyan Bradfute, Steven B. Durvasula, Ravi PLoS One Research Article BACKGROUND: Zika virus (ZIKV) is an emerging pathogen with no approved therapeutics and only limited diagnostics available. To address this gap, six mouse single-chain antibodies (scFvs) to ZIKV envelope (E) protein were isolated rapidly and efficiently from a ribosome-displayed antibody library constructed from the spleens of five immunized mice. METHODOLOGY/RESULTS: In this report, we have generated a panel of mouse scFvs to ZIKV E protein using ribosome display. The six scFvs demonstrated no cross-reactivity with DENV2 NGC envelope protein, suggesting specificity for ZIKV E protein. These scFvs showed differences in their affinity: two (scFv45-3, scFv63-1) of them were dominant after four rounds of panning, and showed higher affinity (an apparent Kd values from 19 to 27 nM) than the other four (scFv5-1, scFv7-2, scFv38-1, and scFv51-2). All six scFvs showed ZIKV-neutralizing activity in the plaque reduction neutralization test (PRNT) assay and their neutralizing activity was positively correlated with their affinities. CONCLUSIONS/SIGNIFICANCE: The scFvs (45–3 and 63–1) with highest affinity may have dual utility as diagnostics capable of recognizing ZIKV E subtypes and may be further developed to treat ZIKV infection. Our approach has the added advantage of generating Fc receptor-deficient antibodies, minimizing concern of antibody-dependent enhancement (ADE) of infection. Public Library of Science 2018-11-16 /pmc/articles/PMC6239285/ /pubmed/30444865 http://dx.doi.org/10.1371/journal.pone.0205743 Text en © 2018 Kunamneni et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Kunamneni, Adinarayana
Ye, Chunyan
Bradfute, Steven B.
Durvasula, Ravi
Ribosome display for the rapid generation of high-affinity Zika-neutralizing single-chain antibodies
title Ribosome display for the rapid generation of high-affinity Zika-neutralizing single-chain antibodies
title_full Ribosome display for the rapid generation of high-affinity Zika-neutralizing single-chain antibodies
title_fullStr Ribosome display for the rapid generation of high-affinity Zika-neutralizing single-chain antibodies
title_full_unstemmed Ribosome display for the rapid generation of high-affinity Zika-neutralizing single-chain antibodies
title_short Ribosome display for the rapid generation of high-affinity Zika-neutralizing single-chain antibodies
title_sort ribosome display for the rapid generation of high-affinity zika-neutralizing single-chain antibodies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6239285/
https://www.ncbi.nlm.nih.gov/pubmed/30444865
http://dx.doi.org/10.1371/journal.pone.0205743
work_keys_str_mv AT kunamneniadinarayana ribosomedisplayfortherapidgenerationofhighaffinityzikaneutralizingsinglechainantibodies
AT yechunyan ribosomedisplayfortherapidgenerationofhighaffinityzikaneutralizingsinglechainantibodies
AT bradfutestevenb ribosomedisplayfortherapidgenerationofhighaffinityzikaneutralizingsinglechainantibodies
AT durvasularavi ribosomedisplayfortherapidgenerationofhighaffinityzikaneutralizingsinglechainantibodies